These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7662001)

  • 1. "Reports of my death [may be] greatly exaggerated" (adapted from Mark Twain)--in response to Dr. J. M. Brown, IJROBP 32:883-885; 1995.
    Coleman CN
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):1264-5. PubMed ID: 7662001
    [No Abstract]   [Full Text] [Related]  

  • 2. Statistical response to Dr. J. M. Brown, IJROBP 32:883-885; 1995.
    Cosmatos D; Pajak TF
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):1265-6. PubMed ID: 7607955
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical science and patient care: lessons from cooperative randomized clinical trials.
    Cox JD
    Int J Radiat Oncol Biol Phys; 1997 Sep; 39(2):273-4. PubMed ID: 9308927
    [No Abstract]   [Full Text] [Related]  

  • 4. End of an era or not? That is the question--in response to Dr. J. M. Brown, IJROBP 32:883-885; 1995.
    Lee DJ; Fu KK; Cooper JS; Wasserman TH
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):1263-4. PubMed ID: 7607954
    [No Abstract]   [Full Text] [Related]  

  • 5. The end of the hypoxic EPOch.
    Aguilera TA; Giaccia AJ
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):895-7. PubMed ID: 25832683
    [No Abstract]   [Full Text] [Related]  

  • 6. Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas.
    Eschwège F; Sancho-Garnier H; Chassagne D; Brisgand D; Guerra M; Malaise EP; Bey P; Busutti L; Cionini L; N'Guyen T; Romanini A; Chavaudra J; Hill C
    Int J Radiat Oncol Biol Phys; 1997 Sep; 39(2):275-81. PubMed ID: 9308928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxic cell radiosensitizers: the end of an era? Regarding Lee et al., IJROBP 32:567-576; 1995.
    Brown JM
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):883-5. PubMed ID: 7790276
    [No Abstract]   [Full Text] [Related]  

  • 8. In regard to Brown et al. (Int J Radiat Oncol Biol Phys 2010;78:323-327).
    Koch CJ; Evans SM
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1604-5; author reply 1605. PubMed ID: 21741000
    [No Abstract]   [Full Text] [Related]  

  • 9. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.
    Lee WR; Berkey B; Marcial V; Fu KK; Cooper JS; Vikram B; Coia LR; Rotman M; Ortiz H
    Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):1069-75. PubMed ID: 9869231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First analysis of tumor regression for the European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas.
    Chassagne D; Charreau I; Sancho-Garnier H; Eschwege F; Malaise EP
    Int J Radiat Oncol Biol Phys; 1992; 22(3):581-4. PubMed ID: 1531218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head and neck cancers: making headway in their treatment?
    McCann J
    J Natl Cancer Inst; 2000 Jan; 92(1):11-3. PubMed ID: 10620623
    [No Abstract]   [Full Text] [Related]  

  • 12. Radiotherapy quality assurance of the IAEA-HypoX trial of the accelerated radiotherapy in the treatment of head and neck squamous cell carcinoma with or without the hypoxic radiosensitizer nimorazole.
    Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Overgaard J; Grau C
    Acta Oncol; 2015; 54(9):1673-7. PubMed ID: 26397148
    [No Abstract]   [Full Text] [Related]  

  • 13. Logistics in designing clinical trials for etanidazole (SR 2508): an RTOG experience.
    Lee DJ; Phillips TL; Coleman CN; Cosmatos D; Davis LW; Wasserman TH; Marcial VA; Rubin P
    Int J Radiat Oncol Biol Phys; 1992; 22(3):569-71. PubMed ID: 1531215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.
    Marcus KJ; Dutton SC; Barnes P; Coleman CN; Pomeroy SL; Goumnerova L; Billett AL; Kieran M; Tarbell NJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1182-5. PubMed ID: 12654425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02).
    Drzymala RE; Wasserman TH; Won M; Shaw E; Cmelak AJ; Loeffler J; Souhami L;
    Radiother Oncol; 2008 Apr; 87(1):89-92. PubMed ID: 18342381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Docetaxel in the inductive therapy of head and neck cancer: recent evidence].
    Benasso M; Corvò R
    Tumori; 2008; 94(4):suppl 24-5. PubMed ID: 18822713
    [No Abstract]   [Full Text] [Related]  

  • 17. Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer.
    Bakowski MT; Macdonald E; Mould RF; Cawte P; Sloggem J; Barrett A; Dalley V; Newton KA; Westbury G; James SE; Hellmann K
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):115-9. PubMed ID: 344287
    [No Abstract]   [Full Text] [Related]  

  • 18. [Docetaxel: a new weapon in the treatment of head and neck tumors].
    Melano M
    Tumori; 2001; 87(6):A9-10. PubMed ID: 11995709
    [No Abstract]   [Full Text] [Related]  

  • 19. Dose-response relationships for late radiation effects in the head and neck: regarding the analysis of the RTOG 8313 trial, Fu et al. IJROBP 32:577-588; 1995.
    Bentzen SM; Thames HD
    Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):523-5. PubMed ID: 8567362
    [No Abstract]   [Full Text] [Related]  

  • 20. Cisplatin as a radiosensitizer in the treatment of locally advanced head and neck cancer.
    Altundag O; Altundag K; Morandi P; Hanrahan E
    Oral Oncol; 2005 Apr; 41(4):435. PubMed ID: 15792617
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.